Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia
Board of Directors

The Company's Board of Directors curently includes the independent outside Director Kenneth Narducy, PhD MBA.  He has completed over $1B in pharmaceutical transactions and products.